All lobbying filings

Ricchetti Incorporated

Ricchetti Incorporated filed a Q2 termination report for Ipsen Biopharmaceuticals, Inc. on July 21, 2025, reporting $20,000 in lobbying income.

Lobbying for Ipsen Biopharmaceuticals, Inc. · Biopharmaceutical company

As filed: RICCHETTI INCORPORATED for IPSEN BIOPHARMACEUTICALS, INC.

All filings by Ricchetti Incorporated · Everything Ipsen Biopharmaceuticals, Inc. has reported

Filing · LD-2 quarterly report Q2 termination

Reporting period

2nd Quarter 2025

Apr 1 - June 30 · Posted Jul 21, 2025

Income

$20,000

What the client paid this registrant for the period.

Client based in

Massachusetts

Representation ended

Jun 30, 2025

The registrant reported terminating its work for this client.

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Pharmacy

Issues related to pharmaceutical industry, generally; Issues related to development of products to treat limb spasticity and fibrodysplasia ossificans progressiva (FOP)

Medicare/Medicaid

Issues related to coverage of diagnostic testing for cancer; H.R.842/S.339, Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act

Bills named in this filing 2

H.R. 842
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
S. 339
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.